Snapshot from Aug 13, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Regulatory / Diagnos receives Health Canada...
Regulatory regulatory approval

Diagnos receives Health Canada licence for CARA

Analysis based on 6 articles · First reported Jul 27, 2026 · Last updated Jul 27, 2026

Sentiment
30
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The Canada — Health Canada licence opens the Canadian optometry market for Diagnosis, potentially increasing revenue. However, the event is a routine regulatory milestone for a small-cap company, so market impact is limited.

Healthcare Medical Devices Artificial Intelligence
Event Summary

On July 23, 2026, Diagnosis Inc. received a Canada — Health Canada Medical Device Licence (Class II) authorizing commercialization of its CARA System in Canada. CARA is an AI-powered retinal image analysis platform that includes modules for age-related macular degeneration detection, diabetic retinopathy detection, retinal microvascular analysis, image enhancement, and a clinician workspace. This licence allows Diagnosis to deliver services to IRIS The Visual Group and deploy its marketing strategy in Canada. The company is also pursuing regulatory approvals from the Saudi Arabia — Saudi Food and Drug Authority and the U.S. United States — Food and Drug Administration.

Entities Involved
govactor
Canada — Health Canada
Canada — Health Canada granted a Class II medical device licence to Diagnosis for the CARA System, marking a regulatory approval.
Importance 80.0 Sentiment 0.0
cnt
Canada
Canada is the country where the Canada — Health Canada licence was granted, enabling commercialization in the Canadian optometry market.
Importance 50.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
Diagnosis plans to submit CARA System application to FDA by September 2026; a legacy version is already cleared in the U.S.
Importance 40.0 Sentiment 0.0
govactor
Saudi Arabia — Saudi Food and Drug Authority
Diagnosis has submitted CARA for marketing approval to SFDA and is addressing queries; approval is pending.
Importance 40.0 Sentiment 0.0
priv
IRIS The Visual Group
IRIS The Visual Group is a customer of Diagnosis; the licence allows Diagnosis to deliver services to them.
Importance 30.0 Sentiment 0.0
cnt
United States
The U.S. is a target market where Diagnosis plans to submit CARA to the FDA; a legacy version is already cleared.
Importance 20.0 Sentiment 0.0
per
André Larente
André Larente is President and CEO of Diagnosis, commented on the achievement.
Importance 20.0 Sentiment 0.0
cnt
Saudi Arabia
Saudi Arabia is a target market where Diagnosis is seeking SFDA approval for CARA.
Importance 20.0 Sentiment 0.0
per
Philippe Couillard
Philippe Couillard is chairman of the board of Diagnosis, praised the achievement for Quebec's innovation ecosystem.
Importance 15.0 Sentiment 0.0
per
Yves-Stephane Couture
Yves-Stephane Couture is COO of Diagnosis, expressed excitement about bringing CARA to Canadian optometrists.
Importance 10.0 Sentiment 0.0
exch
TSX Venture Exchange
TSX Venture Exchange is the stock exchange where Diagnosis is listed; the news release was filed with them.
Importance 5.0 Sentiment 0.0
Relationships
Canada — Health Canada related ↔ Canada
Canada — Health Canada related ↔ United States — Food and Drug Administration
Canada — Health Canada related ↔ United States
Canada related ↔ United States — Food and Drug Administration
Canada trade rivals ↔ United States Canada views the United States as a strained partner and trade rival, facing significant tariffs and renegotiation of tr
Canada related ↔ Saudi Arabia
United States — Food and Drug Administration related ↔ United States
United States strategic allies ↔ Saudi Arabia The United States considers Saudi Arabia a vital strategic ally and energy partner in the Middle East, providing militar
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.